Treatment of Multidrug-resistant Tuberculosis

Tuberculosis is one of the most deadly infectious diseases that still causes significant burden of disease, particularly in the developing world.  The emergence of resistance to first line agents severely limits the therapeutic options and threaten the ability to control dissemination of this disease. Fortunately, new drugs and regimens are now emerging as important alternatives against these organisms.  Today, we will discuss this topic with outstanding experts in the field. Welcome to the editors in conversation. Topics discussed: The burden of multidrug-resistant TB. New drugs and regimens for MDR TB. The current and future pipeline for TB Guests: Kelly Dooley, MD Ph.D.  Professor and Addison B. Scoville, Jr., Chair in Medicine, Director, Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center. Past Editor of AAC Sean Wasserman, MD Ph.D, Reader in Infectious Diseases at St Georges University of London and Associate Professor in the Division of Infectious Diseases and HIV Medicine at University of Cape Town, SA. Editor of AAC. This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up. Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript. Subscribe to Editors in Conversation (free) on Apple Podcasts, Google Podcasts, Android, Spotify, Email.

There are no comments yet.

Please log in to write the first comment.